{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:49:30Z","timestamp":1792615770320,"version":"4.5.0"},"reference-count":34,"publisher":"American Veterinary Medical Association (AVMA)","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>To investigate safety and effectiveness of velagliflozin oral solution as sole therapy in na\u00efve and previously insulin-treated diabetic cats.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>ANIMALS<\/jats:title>\n<jats:p>252 client-owned cats receiving \u2265 2 doses of velagliflozin; 214 (85%) na\u00efve diabetics and 38 (15%) insulin-treated diabetics.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>PROCEDURES<\/jats:title>\n<jats:p>Prospective, baseline-controlled, open-label clinical field trial. Cats received velagliflozin orally, once daily. Physical examinations and blood collections were performed days 0, 3, 7, 30, 60, 120, and 180.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS<\/jats:title>\n<jats:p>Data are median (range). Screening blood glucose (BG) was 436 mg\/dL (272 to 676 mg\/dL). On days 30, 60, 120, and 180, single BG after receiving velagliflozin was 153 mg\/dL (62 to 480 mg\/dL), 134 mg\/dL (64 to 414 mg\/dL), 128 mg\/dL (55 to 461 mg\/dL), and 125 mg\/dL (77 to 384 mg\/dL), respectively. Screening fructosamine was 538 \u00b5mol\/L (375 to 794 \u00b5mol\/L). On the same recheck days, fructosamine was 310 \u00b5mol\/L (204 to 609 \u00b5mol\/L), 286 \u00b5mol\/L (175 to 531 \u00b5mol\/L), 269 \u00b5mol\/L (189 to 575 \u00b5mol\/L), and 263 \u00b5mol\/L (203 to 620 \u00b5mol\/L). At day 180, 81% of 158 cats remaining had BG and\/or fructosamine within reference ranges; 88.6% (124 of 140) and 87.7% (121 of 138) showed improvement in polyuria and polydipsia, respectively. Ketonuria developed in 35 cats (13.9%), including 18 (7.1%) that had ketoacidosis. Ketoacidosis was less common in na\u00efve diabetic cats (11 of 214 [5.1%]) compared to insulin-treated diabetic cats (7 of 38 [18.4%]). At ketoacidosis diagnosis, 14 of 18 cats (77.8%) were euglycemic (ie, BG &lt; 250 mg\/dL). Most episodes of ketosis or ketoacidosis (30 of 35 [85.7%]) occurred within the first 14 days of treatment. Insulin-treated diabetic cats were less likely to complete the trial. No clinical hypoglycemia occurred.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CLINICAL RELEVANCE<\/jats:title>\n<jats:p>Velagliflozin improved glycemic parameters and clinical signs in diabetic cats. Velagliflozin provides an alternative to insulin as a stand-alone treatment of diabetic cats.<\/jats:p>\n<\/jats:sec>","DOI":"10.2460\/javma.24.03.0174","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T16:02:12Z","timestamp":1723651332000},"page":"1343-1353","source":"Crossref","is-referenced-by-count":19,"title":["Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study"],"prefix":"10.2460","volume":"262","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5010-2983","authenticated-orcid":true,"given":"Ellen N.","family":"Behrend","sequence":"first","affiliation":[{"name":"Veterinary Information Network, Davis, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia R.","family":"Ward","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Georgia, Athens, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Chukwu","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Animal Health USA Inc, Duluth, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey K.","family":"Cook","sequence":"additional","affiliation":[{"name":"Department of Small Animal Clinical Sciences, School of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Kroh","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty","family":"Lathan","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacky","family":"May","sequence":"additional","affiliation":[{"name":"Scout Bio, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6800-0969","authenticated-orcid":true,"given":"Thomas","family":"Schermerhorn","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Catharine","family":"Scott-Moncrieff","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Voth","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Animal Health USA Inc, St Joseph, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"issue":"5","key":"ref1","series-title":"J Feline Med Surg","first-page":"351","article-title":"Time trends and risk factors for diabetes mellitus in cats presented to veterinary teaching hospitals","volume":"9","author":"Prahl A","year":"2007","unstructured":"Prahl A, Guptill L, Glickman NW, Tetrick M, Glickman LT. Time trends and risk factors for diabetes mellitus in cats presented to veterinary teaching hospitals. J Feline Med Surg. 2007;9(5):351-358. doi:10.1016\/j.jfms.2007.02.004"},{"issue":"4","key":"ref2","series-title":"J Vet Intern Med","first-page":"964","article-title":"Epidemiology of diabetes mellitus among 193,435 cats attending primary-care veterinary practices in England","volume":"30","author":"O\u2019Neill DG","year":"2016","unstructured":"O\u2019Neill DG, Gostelow R, Orme C,  Epidemiology of diabetes mellitus among 193,435 cats attending primary-care veterinary practices in England. J Vet Intern Med. 2016;30(4):964-972. doi:10.1111\/jvim.14365"},{"issue":"4","key":"ref3","series-title":"J Feline Med Surg","first-page":"289","article-title":"Feline diabetes mellitus in the UK: the prevalence within an insured cat population and a questionnaire-based putative risk factor analysis","volume":"9","author":"McCann TM","year":"2007","unstructured":"McCann TM, Simpson KE, Shaw DJ, Butt JA, Gunn-Moore DA. Feline diabetes mellitus in the UK: the prevalence within an insured cat population and a questionnaire-based putative risk factor analysis. J Feline Med Surg. 2007;9(4):289-299. doi:10.1016\/j.jfms.2007.02.001"},{"issue":"3","key":"ref4","series-title":"Vet Clin North Am Small Anim Pract","first-page":"511","article-title":"Pathophysiology of prediabetes, diabetes, and diabetic remission in cats","volume":"53","author":"Gostelow R","year":"2023","unstructured":"Gostelow R, Hazuchova K. Pathophysiology of prediabetes, diabetes, and diabetic remission in cats. Vet Clin North Am Small Anim Pract. 2023;53(3):511-529. doi:10.1016\/j.cvsm.2023.02.001"},{"key":"ref5","series-title":"Gen Comp Endocrinol","first-page":"48","article-title":"Diabetes from humans to cats","volume":"182","author":"Osto M","year":"2013","unstructured":"Osto M, Zini E, Reusch CE, Lutz TA. Diabetes from humans to cats. Gen Comp Endocrinol. 2013;182:48-53. doi:10.1016\/j.ygcen.2012.11.019"},{"issue":"suppl 1","key":"ref6","series-title":"Diabetes","first-page":"S119","article-title":"\u03b2-Cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes","volume":"53","author":"Robertson RP","year":"2004","unstructured":"Robertson RP, Harmon J, Tran POT, Poitout V. \u03b2-Cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53(suppl 1):S119-S124. doi:10.2337\/diabetes.53.2007.S119"},{"issue":"2","key":"ref7","series-title":"Diabetologia","first-page":"336","article-title":"Hyperglycaemia but not hyperlipidaemia causes beta cell dysfunction and beta cell loss in the domestic cat","volume":"52","author":"Zini E","year":"2009","unstructured":"Zini E, Osto M, Franchini M,  Hyperglycaemia but not hyperlipidaemia causes beta cell dysfunction and beta cell loss in the domestic cat. Diabetologia. 2009;52(2):336-346. doi:10.1007\/s00125-008-1201-y"},{"issue":"1","key":"ref8","series-title":"J Am Anim Hosp Assoc","first-page":"1","article-title":"2018 AAHA diabetes management guidelines for dogs and cats","volume":"54","author":"Behrend E","year":"2018","unstructured":"Behrend E, Holford A, Lathan P, Rucinsky R, Schulman R. 2018 AAHA diabetes management guidelines for dogs and cats. J Am Anim Hosp Assoc. 2018;54(1):1-21. doi:10.5326\/JAAHA-MS-6822"},{"issue":"2","key":"ref9","series-title":"Vet Sci","first-page":"4","article-title":"The big pet diabetes survey: perceived frequency and triggers for euthanasia","volume":"4","author":"Niessen SJM","year":"2017","unstructured":"Niessen SJM, Hazuchova K, Powney SL,  The big pet diabetes survey: perceived frequency and triggers for euthanasia. Vet Sci. 2017;4(2):4. doi:10.3390\/vetsci4020027"},{"key":"ref10","series-title":"Biochem Pharmacol","first-page":"27","article-title":"SGLT2 inhibitors","volume":"101","author":"Dardi I","year":"2016","unstructured":"Dardi I, Kouvatsos T, Jabbour SA. SGLT2 inhibitors. Biochem Pharmacol. 2016;101:27-39. doi:10.1016\/j.bcp.2015.09.005"},{"issue":"2","key":"ref11","series-title":"Endocr Rev","first-page":"187","article-title":"\u03b2-Cell failure in diabetes and preservation by clinical treatment","volume":"28","author":"Wajchenberg BL","year":"2007","unstructured":"Wajchenberg BL. \u03b2-Cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187-218. doi:10.1210\/10.1210\/er.2006-0038"},{"issue":"2","key":"ref12","series-title":"J Vet Pharmacol Ther","first-page":"266","article-title":"Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats","volume":"41","author":"Hoenig M","year":"2018","unstructured":"Hoenig M, Clark M, Schaeffer DJ, Reiche D. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. J Vet Pharmacol Ther. 2018;41(2):266-273. doi:10.1111\/jvp.12467"},{"key":"ref13","series-title":"J Vet Intern Med","first-page":"2455","article-title":"Once daily oral therapy for feline diabetes mellitus: SGLT-2-inhibitor velagliflozin as stand-alone therapy compared to insulin injection therapy in diabetic cats","volume":"36","author":"Niessen SJM","year":"2022","unstructured":"Niessen SJM, Voth R, Kroh C, Hennings L. Once daily oral therapy for feline diabetes mellitus: SGLT-2-inhibitor velagliflozin as stand-alone therapy compared to insulin injection therapy in diabetic cats. J Vet Intern Med. 2022;36:2455-2551. 32nd ECVIM-CA Congress abstract 101 ESVE-O-11."},{"issue":"1","key":"ref14","series-title":"Can J Vet Res","first-page":"52","article-title":"Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus","volume":"86","author":"Benedict SL","year":"2022","unstructured":"Benedict SL, Mahony OM, McKee TS, Bergman PJ. Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus. Can J Vet Res. 2022;86(1):52-58."},{"issue":"3","key":"ref15","series-title":"J Vet Intern Med","first-page":"915","article-title":"Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus","volume":"37","author":"Hadd MJ","year":"2023","unstructured":"Hadd MJ, Bienhoff SE, Little SE,  Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus. J Vet Intern Med. 2023;37(3):915-924. doi:10.1111\/jvim.16730"},{"key":"ref16","series-title":"Vet J","first-page":"105910","article-title":"ESVE\/SCE membership. Agreeing Language in Veterinary Endocrinology (ALIVE): diabetes mellitus\u2014a modified Delphi-method-based system to create consensus disease definitions","volume":"289","author":"Niessen SJM","year":"2022","unstructured":"Niessen SJM, Bjornvad C, Church DB, ; ESVE\/SCE membership. Agreeing Language in Veterinary Endocrinology (ALIVE): diabetes mellitus\u2014a modified Delphi-method-based system to create consensus disease definitions. Vet J. 2022;289:105910. doi:10.1016\/j.tvjl.2022.105910"},{"key":"ref17","article-title":"Freedom of Information summary, original new animal drug application: NADA 141-568 Senvelgo (velagliflozin oral solution)","author":"FDA","unstructured":"FDA. Freedom of Information summary, original new animal drug application: NADA 141-568 Senvelgo (velagliflozin oral solution). August 10, 2023. Accessed February 7, 2024. https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/14320"},{"issue":"6","key":"ref18","series-title":"J Vet Diagn Invest","first-page":"710","article-title":"Impact on result interpretation of correct and incorrect selection of veterinary glucometer canine and feline settings","volume":"35","author":"Pe\u00f1a LW","year":"2023","unstructured":"Pe\u00f1a LW, Flatland B, Behrend EN, Arz\u00f3n-Pereira A, Cole JE, Raz ML. Impact on result interpretation of correct and incorrect selection of veterinary glucometer canine and feline settings. J Vet Diagn Invest. 2023;35(6):710-720. doi:10.1177\/10406387231195386"},{"key":"ref19","series-title":"Am J Emerg Med","first-page":"157","article-title":"Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management","volume":"44","author":"Long B","year":"2021","unstructured":"Long B, Lentz S, Koyfman A, Gottlieb M. Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management. Am J Emerg Med. 2021;44:157-160. doi:10.1016\/j.ajem.2021.02.015"},{"issue":"5","key":"ref20","series-title":"PLoS One","first-page":"e0127794","article-title":"Studying cat (Felis catus) diabetes: beware of the acromegalic imposter","volume":"10","author":"Niessen SJ","year":"2015","unstructured":"Niessen SJ, Forcada Y, Mantis P,  Studying cat (Felis catus) diabetes: beware of the acromegalic imposter. PLoS One. 2015;10(5):e0127794. doi:10.1371\/journal.pone.0127794"},{"issue":"5","key":"ref21","series-title":"J Feline Med Surg","first-page":"439","article-title":"Treatment of 46 cats with porcine lente insulin\u2014a prospective, multicentre study","volume":"10","author":"Michiels L","year":"2008","unstructured":"Michiels L, Reusch CE, Boari A,  Treatment of 46 cats with porcine lente insulin\u2014a prospective, multicentre study. J Feline Med Surg. 2008;10(5):439-451. doi:10.1016\/j.jfms.2007.10.013"},{"issue":"4","key":"ref22","series-title":"J Vet Intern Med","first-page":"787","article-title":"Field safety and efficacy of protamine zinc recombinant human insulin for treatment of diabetes mellitus in cats","volume":"23","author":"Nelson RW","year":"2009","unstructured":"Nelson RW, Henley K, Cole C; PZIR Clinical Study Group. Field safety and efficacy of protamine zinc recombinant human insulin for treatment of diabetes mellitus in cats. J Vet Intern Med. 2009;23(4):787-793. doi:10.1111\/j.1939-1676.2009.0342.x"},{"issue":"8","key":"ref23","series-title":"J Feline Med Surg","first-page":"566","article-title":"Evaluation of detemir in diabetic cats managed with a protocol for intensive blood glucose control","volume":"14","author":"Roomp K","year":"2012","unstructured":"Roomp K, Rand J. Evaluation of detemir in diabetic cats managed with a protocol for intensive blood glucose control. J Feline Med Surg. 2012;14(8):566-572. doi:10.1177\/1098612X12446211"},{"issue":"8","key":"ref24","series-title":"J Feline Med Surg","first-page":"668","article-title":"Intensive blood glucose control is safe and effective in diabetic cats using home monitoring and treatment with glargine","volume":"11","author":"Roomp K","year":"2009","unstructured":"Roomp K, Rand J. Intensive blood glucose control is safe and effective in diabetic cats using home monitoring and treatment with glargine. J Feline Med Surg. 2009;11(8):668-682. doi:10.1016\/j.jfms.2009.04.010"},{"issue":"4","key":"ref25","series-title":"J Vet Intern Med","first-page":"2099","article-title":"Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats","volume":"38","author":"Niessen SJM","year":"2024","unstructured":"Niessen SJM, Kooistra HS, Forcada Y,  Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats. J Vet Intern Med. 2024;38(4):2099-2119. doi:10.1111\/jvim.17124"},{"key":"ref26","article-title":"Freedom of Information summary, original new animal drug application: NADA 141-566 Bexacat (bexagliflozin tablets)","author":"FDA","unstructured":"FDA. Freedom of Information summary, original new animal drug application: NADA 141-566 Bexacat (bexagliflozin tablets). December 8, 2022. Accessed December 9, 2022. https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/13222"},{"issue":"6","key":"ref27","series-title":"J Vet Intern Med","first-page":"1314","article-title":"Predictors of clinical remission in cats with diabetes mellitus","volume":"24","author":"Zini E","year":"2010","unstructured":"Zini E, Hafner M, Osto M,  Predictors of clinical remission in cats with diabetes mellitus. J Vet Intern Med. 2010;24(6):1314-1321. doi:10.1111\/j.1939-1676.2010.0598.x"},{"issue":"6","key":"ref28","series-title":"J Feline Med Surg","first-page":"506","article-title":"Priorities on treatment and monitoring of diabetic cats from the owners\u2019 points of view","volume":"22","author":"Albuquerque CS","year":"2020","unstructured":"Albuquerque CS, Bauman BL, Rzeznitzeck J, Caney SM, Gunn-Moore DA. Priorities on treatment and monitoring of diabetic cats from the owners\u2019 points of view. J Feline Med Surg. 2020;22(6):506-513. doi:10.1177\/1098612X19858154"},{"issue":"5","key":"ref29","series-title":"BMJ Open Diabetes Res Care","first-page":"11","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow E","year":"2023","unstructured":"Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2023;11(5):11. doi:10.1136\/bmjdrc-2023-003666"},{"issue":"1","key":"ref30","series-title":"J Small Anim Pract","first-page":"4","article-title":"Ketone measurements using dipstick methodology in cats with diabetes mellitus","volume":"50","author":"Zeugswetter F","year":"2009","unstructured":"Zeugswetter F, Pagitz M. Ketone measurements using dipstick methodology in cats with diabetes mellitus. J Small Anim Pract. 2009;50(1):4-8. doi:10.1111\/j.1748-5827.2008.00657.x"},{"issue":"4","key":"ref31","series-title":"Can Vet J","first-page":"399","article-title":"Loose-control of diabetes mellitus with protamine zinc insulin in cats: 185 cases (2005-2015)","volume":"60","author":"Restine LM","year":"2019","unstructured":"Restine LM, Norsworthy GD, Kass PH. Loose-control of diabetes mellitus with protamine zinc insulin in cats: 185 cases (2005-2015). Can Vet J. 2019;60(4):399-404."},{"issue":"3","key":"ref32","series-title":"Postgrad Med","first-page":"382","article-title":"Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"129","author":"Devi R","year":"2017","unstructured":"Devi R, Mali G, Chakraborty I, Unnikrishnan MK, Abdulsalim S. Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Postgrad Med. 2017;129(3):382-392. doi:10.1080\/00325481.2017.1259544"},{"issue":"4","key":"ref33","series-title":"J Vet Intern Med","first-page":"850","article-title":"Frequency and risk factors for urinary tract infection in cats with diabetes mellitus","volume":"20","author":"Bailiff NL","year":"2006","unstructured":"Bailiff NL, Nelson RW, Feldman EC,  Frequency and risk factors for urinary tract infection in cats with diabetes mellitus. J Vet Intern Med. 2006;20(4):850-855. doi:10.1111\/j.1939-1676.2006.tb01797.x"},{"issue":"2","key":"ref34","series-title":"J Feline Med Surg","first-page":"124","article-title":"Urinary tract infections in cats with hyperthyroidism, diabetes mellitus and chronic kidney disease","volume":"9","author":"Mayer-Roenne B","year":"2007","unstructured":"Mayer-Roenne B, Goldstein RE, Erb HN. Urinary tract infections in cats with hyperthyroidism, diabetes mellitus and chronic kidney disease. J Feline Med Surg. 2007;9(2):124-132. doi:10.1016\/j.jfms.2006.09.004"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/262\/10\/javma.24.03.0174.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/262\/10\/javma.24.03.0174.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/262\/10\/javma.24.03.0174.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T14:08:51Z","timestamp":1741356531000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/262\/10\/javma.24.03.0174.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":34,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.2460\/javma.24.03.0174","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}